Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure

Purpose Ripasudil accelerates aqueous humour drainage along the trabecular meshwork—Schlemm’s canal route and has been approved for clinical use in Japan. We retrospectively investigated the efficacy and safety of adding ripasudil to existing treatment regimens to reduce intraocular pressure (IOP) in patients with glaucoma.